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Abstract
Background: Although radical surgery remains the cornerstone of cure in resectable gastric cancer, survival remains poor.
Current evidence-based (neo)adjuvant strategies have shown to improve outcome, including perioperative chemotherapy,
postoperative chemoradiotherapy and postoperative chemotherapy. However, these regimens suffer from poor patient
compliance, particularly in the postoperative phase of treatment. The CRITICS-II trial aims to optimize preoperative
treatment by comparing three treatment regimens: (1) chemotherapy, (2) chemotherapy followed by chemoradiotherapy
and (3) chemoradiotherapy.
Methods: In this multicentre phase II non-comparative study, patients with clinical stage IB-IIIC (TNM 8th edition)
resectable gastric adenocarcinoma are randomised between: (1) 4 cycles of docetaxel+oxaliplatin+capecitabine (DOC), (2)
2 cycles of DOC followed by chemoradiotherapy (45Gy in combination with weekly paclitaxel and carboplatin) or (3)
chemoradiotherapy. Primary endpoint is event-free survival, 1 year after randomisation (events are local and/or regional
recurrence or progression, distant recurrence, or death from any cause). Secondary endpoints include: toxicity, surgical
outcomes, percentage radical (R0) resections, pathological tumour response, disease recurrence, overall survival, and health
related quality of life. Exploratory endpoints include translational studies on predictive and prognostic biomarkers.
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Discussion: The aim of this study is to select the most promising among three preoperative treatment arms in patients
with resectable gastric adenocarcinoma. This treatment regimen will subsequently be compared with the standard
therapy in a phase III trial.
Trial registration: clinicaltrials.gov NCT02931890; registered 13 October 2016. Date of first enrolment: 21 December 2017.
Keywords: Gastric cancer, Resectable, Preoperative treatment, Chemotherapy, Chemoradiotherapy, Surgery
Background
Gastric cancer is the fifth most common malignancy
worldwide [1]. In Western countries, gastric cancer pa-
tients often present with advanced disease. The 5-year
survival rate after surgery alone in resectable gastric can-
cer is 20–35% [2, 3]. To improve these poor outcomes,
different strategies have been evaluated.
Based on the Dutch D1D2 trial, D2 lymphadenectomy
with removal of at least 15 lymph nodes is the current
recommended surgical approach in patients with poten-
tially curable gastric cancer [4].
In addition to a more extended resection, several (neo-)-
adjuvant treatments have been evaluated in phase II and
III trials. An overview of all published and ongoing rando-
mised (neo-)adjuvant clinical trials in resectable gastric
and/or gastro-oesophageal junction (GOJ) cancer pub-
lished since 1990 is provided in Table 1.
In the SWOG/Intergroup trial, 556 patients with
resectable gastric or GOJ cancer were randomised
between surgery alone versus surgery plus postopera-
tive chemoradiotherapy (CRT) (45 Gy plus 5-fluorouracil
(5-FU) and leucovorin). The CRT arm showed signifi-
cantly improved overall survival (OS) [5]. The three-year
OS rates were 41% in the surgery alone group compared
to 50% in the CRT group [5]. An updated analysis showed
persistent benefit from adjuvant CRT [6].
In 2005, the final results of the MAGIC trial were pre-
sented. In this trial, 503 patients with resectable adenocar-
cinoma of the stomach, GOJ or lower oesophagus were
randomised to either perioperative chemotherapy (CT) or
surgery alone. Chemotherapy consisted of 3 preoperative
and 3 postoperative cycles of epirubicin, cisplatin and 5-FU
(ECF). This perioperative regimen of ECF significantly de-
creased tumour size and induced downstaging. The
five-year OS improved significantly from 23% in the surgery
alone group to 36% in the perioperative CT group [7].
Many studies have investigated the effect of postoperative
CT on survival rates. A meta-analysis from the GASTRIC
Group, published in 2010, revealed a significant survival
benefit favouring postoperative fluorouracil regimens with a
hazard ratio of 0.82 (95% confidence interval (95%CI) 0.76–
0.90; p < 0.001). The five-year OS increased from 49.6 to
55.3% with postoperative CT. It should be noted that a sub-
stantial number of the 17 included studies were carried out
in Asia, where patient populations, tumour characteristics
and surgical procedures are different compared to the
Western world [8].
Current European guidelines include multiple (neo-)-
adjuvant treatments for patients with resectable gastric
cancer [9]. The CRITICS-study was designed to compare
OS between patients treated with preoperative CT followed
by surgery and postoperative CT versus postoperative CRT
[10]. Postoperative CRT did not improve OS as compared
to postoperative CT after adequate preoperative CT and
surgery [11]. Hence, multiple treatment options remain cur-
rently available for patients with locally advanced, resectable
gastric cancer. Which patients benefit from which (neo)ad-
juvant strategy should be addressed in future clinical trials.
There are several important issues that should be ad-
dressed in such future studies; which form the rationale
behind the CRITICS-II trial. First of all, in most (neo)ad-
juvant studies patient compliance is low, especially in
the postoperative phase (Table 2): 40–60% of patients
are not able to complete treatment, mostly due to tox-
icity, disease progression or patient refusal. Second,
there is need for more effective (neo-) adjuvant treat-
ment with equal/less toxicity compared to the widely
used epirubicin containing CT. Replacing epirubicin by
docetaxel seems to be more effective [12–14], and is
considered safe and tolerable [15]. Third, preoperative
treatment increases the likelihood of tumour downsizing/
downstaging and to achieve surgical radical (R0) resection,
as shown in the MAGIC and the CROSS trials [7, 16]. An
overview article reported 70–100% radical (R0) resections
and a pathological Complete Reponse (pCR) of 7–29% in
patients with resectable gastric cancer, preoperatively
treated with CRT [17].
Finally, preoperative (C)RT allows a more accurate def-
inition of the radiation target volume and margins com-
pared to postoperative (C)RT, which may potentially
limit toxicity. For oesophageal cancer, preoperative CRT
showed improved survival with acceptable toxicity rates
and > 90% patients being able to complete the entire
treatment [16].
Based on these considerations, the aim of the current
study is to optimise preoperative treatment by compar-
ing three neo-adjuvant treatment modalities: (1) CT, (2)
CT plus CRT, and (3) CRT.
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Methods
Study design and objectives
The CRITICS-II study is a multicentre, non-comparative
randomised phase II trial. The study is currently recruiting
in several centres in The Netherlands. Randomisation is
computer generated and will be performed and registered
by the data managers. Stratification factors include Lauren
classification (intestinal, diffuse, unclassifiable) and centre.
The primary objective is to assess 1 year event-free sur-
vival in patients treated with preoperative CT, preopera-
tive CT followed by CRT, or preoperative CRT (Fig. 1).
Event-free survival (EFS) is defined as interval between
randomisation and local and/or regional recurrence or pro-
gression, distant recurrence or death from any cause.
Secondary endpoints are: toxicity, percentage radical
(R0) resections, pathological tumour response, disease
recurrence, overall survival and health related quality of
life (HRQOL). Exploratory endpoints include transla-
tional studies into the relationship between classical
histological and clinical parameters, the identification of
new biomarkers that predict clinical outcome and re-
sponse, genomic changes in circulating tumour-derived
DNA for diagnosis of different molecular subtypes of
gastric cancer, and as biomarkers for response to
treatment.
Patient selection and preoperative staging
Patients will be informed and treated by their treating
physician. Patients with histologically proven, stage
IB-IIIC (TNM 8th edition), resectable gastric adenocar-
cinoma are eligible for this study. Patients with tumours
at the gastro-oesophageal junction (GOJ) may be in-
cluded, but the tumour bulk has to be in the stomach.
Patients should be ≥18 years old and should have WHO
performance status < 2. Patients must have adequate
haematological, renal and liver function. A staging lapar-
oscopy is mandatory for all patients. At staging laparos-
copy, biopsies from suspicious peritoneal lesions and/or
free peritoneal fluid if any, should be pathologically proven
tumour negative. Patients should have caloric intake
≥1500 kcal/day, verified by a dietician before registration.
If caloric intake is < 1500 kcal/day or if bodyweight has
decreased > 10% over the last 6 months or > 5% over the
last month, dietary intervention such as oral nutritional
support or via an enteral feeding tube is mandatory.
Exclusion criteria include: T1 N0 disease (assessed by
endoscopic ultrasound), distant metastasis, inoperable/
irresectable patients, previous malignancy, solitary func-
tioning kidney within the potential radiation field and
gastro-oesophageal stent within the radiation field. Re-
quired baseline investigations prior to randomisation
consist of blood tests, dietician visit, oesophagoduodeno-
scopy with representative tumour biopsy samples, com-
puted tomography of the chest and abdomen, staging
laparoscopy, renography if there are signs on computed
tomography abdomen and/or biochemically signs of im-
paired renal function. Endoscopic ultrasound (for
>T1 N0 disease) and performing a FDG-PET/ computed
tomography scan are optional per centre.
Table 2 Patient compliance in various recent or ongoing
clinical trials in resectable gastric cancer
Study [reference] Treatment arm Completed (%)
SWOG [5] S→CRT 64%
MAGIC [7] CT→S→CT 42%
ACTS-GC [51] S→CT 66%
CLASSIC [40] S→CT 67%
ARTIST [59] S→CT 75%
S→CRT 82%
ST03 [31] CT→S→CT 40%
CT + B→S→CT + B 37%
TOPGEAR part 1 [27] CT→S→CT 58%
CT→CRT→S→CT 45%
FLOT4-AIO [14] CT→S→CT (3×ECF/ECX) 37%
CT→S→CT (4×FLOT) 50%
CRITICS [11] CT→S→CT 46%
CT→S→CRT 51%
CT chemotherapy, CRT chemoradiotherapy, S surgery, B bevacizumab
Fig. 1 Randomisation scheme CRITICS-II trial
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Treatment arms
All treatment arms will start within 15 working days after
randomisation. Patients in arm 1 receive four cycles of do-
cetaxel+oxaliplatin+capecitabine (DOC) at a three-weekly
interval preoperatively. Patients in arm 2 receive two cy-
cles of DOC at a three-weekly interval, followed by CRT
(weekly paclitaxel and carboplatin concurrent with radio-
therapy). Chemoradiotherapy starts 3 weeks after start of
the second DOC cycle. Patients in arm 3 receive CRT.
Prior to surgery, a computed tomography will be per-
formed to exclude progressive disease.
Patients can withdraw their informed consent at any time
for any reason if they wish so without any consequences.
The investigator can decide to withdraw a patient from the
study for urgent medical reasons.
Preoperative study treatment: Chemotherapy
Chemotherapeutic treatment consists of docetaxel 50 mg/
m2 on day 1, followed by oxaliplatin 100 mg/m2 on day
one, followed by capecitabine 850 mg/m2 b.i.d. orally on
days 1–14. All drugs are administered in a cycle of 21 days.
For capecitabine, drug tablet return and a diary are pro-
vided. Dose could be discontinued/reduced in case of se-
vere toxicities.
Preoperative study treatment: Chemoradiotherapy
Radiotherapy consists of 45 Gy in 25 fractions of 1.8 Gy, 5
fractions per week for 5 weeks using image guided intensity
modulated radiotherapy/volumic arc therapy (IMRT/
VMAT) techniques. The Clinical Target Volume (CTV)
has to be delineated on CT-images based on all available
diagnostic information and should include the tumour,
stomach and first draining lymph node stations. For quality
assurance, a treatment delineation atlas is available and
planning audits are performed. All delineations will be cen-
trally reviewed and if necessary corrected before start of
treatment.
Concurrent with radiotherapy, weekly CT is adminis-
tered. Paclitaxel at a dose of 50 mg/m2 and carboplatin
Area Under the Curve (AUC) = 2 are given by intravenous
infusion on days 1, 8, 15, 22 and 29. Radiotherapy starts at
the first day of the first cycle of CT. Radiotherapy and/or
chemotherapy dose could be discontinued/reduced in case
of severe toxicities.
Surgery
Surgery is planned 3–4 weeks after preoperative treatment
in arm 1 and 6–8 weeks after preoperative treatment in
arms 2 and 3. The standard surgical procedure is a (sub)-
total gastrectomy with a D2 lymph node dissection. A
minimum of 15 lymph nodes should be removed. Lymph
nodes will be submitted in separate pots, or alternatively,
will be clearly marked at the resection specimen. Surgical
technique is either open or laparoscopic.
Pathology
The pathology report includes at least the following items:
tumour type, localisation, size of tumour, surgical margins,
response to neo-adjuvant therapy in the primary tumour
and the lymph nodes (by nodal station), presence of
lymphatic invasion, presence of venous invasion, surgical
stage, number of (positive) lymph nodes.
All tumours are classified using the Lauren classification
(intestinal, diffuse and unclassifiable). For staging, the
TNM 8th edition is used. Biopsies, photographs, resection
specimen and when performed fresh frozen specimen will
be sent for central pathological review. Pathological re-
sponse according to the Becker scoring system [18] and
the Mandard scoring system [19] will be investigated in
central pathological review.
Quality of life
Health related quality of life will be carried out in co-
operation with the Prospective Observational Cohort
study of Oesophagogastric cancer Patients (POCOP),
which is a prospective nationwide study to investigate
HRQL in oesophagogastric cancer of all stages [20].
Health related quality of life will be assessed at baseline
(before start preoperative treatment), pre-surgery and
from surgery every 3 months in the first year, every
6 months in the second year and yearly thereafter until
5 years.
Translational research: Circulating tumour DNA (ctDNA)
Patients can optionally participate in this part of the proto-
col. All patients participating in this part of the protocol
need to have signed informed consent specifically for this
optional side study of the trial. Blood will be collected at
baseline before start of any of the preoperative treatment
modalities, after every preoperative treatment modality,
after surgery and at every follow-up visit until 5 years after
surgery or until recurrence. Material processing and storage
will be done centrally at the VU University Medical Center.
Toxicity and (serious) adverse events
Toxicity during this trial is scored using the Common
Terminology Criteria for Adverse Events (CTCAE) ver-
sion 4.0. Serious adverse events are defined according to
the rules of good clinical practice and must be reported
within one working day and are reported once yearly in
the annual safety report. The Clavien-Dindo grading sys-
tem is used for the classification of surgical complica-
tions [21].
Follow-up
After treatment, patients are followed by all treating med-
ical specialists. The follow-up moments in the first year
are, counted from surgery, at 1, 3, 6 and 12 months. From
the second year, follow-up will occur every 6 months until
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5 years after surgery. To enable evaluation of the primary
endpoint, one-year EFS, CT chest and abdomen will be
performed 1 year after randomisation.
Protocol amendments
Future protocol modifications will be submitted as amend-
ment at the central medical ethics committee. After obtain-
ing approval, this will be communicated to the participating
sites by the study coordinator or project manager.
Data management and responsibilities
The central data management, data processing and stat-
istical analysis of this study are performed at the Biomet-
ric Department of the sponsor. The study coordinators
are responsible, in cooperation with the Data Centre, for
writing the protocol, reviewing all case report forms,
reporting and correctness of SAE. They are also respon-
sible for answering clinical questions, treatment and
evaluation of the patients and for publishing study re-
sults. Authors on the key-publication includes at least
the protocol writing committee and additional a max-
imum of three authors per centre. The key-publication
will be submitted to a major, peer-reviewed journal. Data
is entered by data managers into a coded electronic
case-report form. The study will be considered as a
medium risk according Dutch Federation of University
Medical Centres guidelines. Site monitoring will be per-
formed by an independent Clinical Research Monitor or
the person to whom the monitoring tasks have been del-
egated. The monitor will judge: compliance with the
protocol, all applicable regulatory requirements, in-
formed consent, source data verification, investigator
study file, SAE/Serious Unexpected Serious Adverse Re-
actions. If necessary, active feedback will be provided to
the participating sites. The study will be monitored and
an auditing trail will not be performed routinely. The
study coordinators will have access to the final dataset.
Queries will be sent in case of missing data.
Statistics
The primary endpoint of this trial is EFS at 1 year. Statis-
tical analysis will be performed on basis of intention to treat
analysis. For each treatment arm, a 1-year EFS of 60% is
considered insufficient and a 1-year EFS of 75% is active
enough to further explore in a phase III study, taking other
endpoints in consideration. The 1-year EFS of 60% is based
on results of the MAGIC [22] and the CRITICS trial [11].
The design calculations assume Weibull distributions
(shape = 1), which is equivalent to an exponential distribu-
tion. Scale parameters were chosen such that 1 year EFS
would be 60% and 75% respectively. The type I (α) error is
fixed at 10% (one-sided) and power is set at 90%.The R
package OptInterim minimising the expected sample size
was used for calculating the sample size for each stage as
well as the time of interim and final analyses. We used
exact binomial correction adjusting all sample size and ana-
lysis times.
The trial is designed as a two-stage trial with one in-
terim analysis at which futile arms are discontinued. Be-
cause the primary endpoint is evaluated at 1 year, the
commonly used Simon’s two stage design would imply up
to 1 year in which the trial would be put on hold. To im-
prove the efficiency, we will use the two stage design for
survival endpoints as proposed by Case and Morgan [23].
The expected accrual is 30 patients per arm per year.
After accruing 42 patients in each arm, the interim analysis
will be performed. Futile arms will be discontinued and the
remaining arms will accrue 27 more patients each (to a
total of 69 patients in each arm). Final analysis will be per-
formed 1 year after accrual of last patient. In both stages
the null hypothesis will be evaluated using Lin’s statistics
[24]. If in the final analysis more than one arm will reject
the null hypothesis, the decision about which arm should
continue to the phase III trial will be made based on the
Kaplan Meier point estimates of the 1-year EFS in combin-
ation with other factors such as toxicity, cost, convenience
and quality of life.
Discussion
Here we describe the study protocol of the CRITICS-II
trial, a clinical phase II study aimed at identifying a new
and optimal preoperative treatment in patients with resect-
able gastric cancer by comparing three preoperative treat-
ment arms. Several considerations have led to the design of
this trial. First, patients’ compliance, especially in the post-
operative phase of the treatment, is low (Table 2). Second,
there is need for a more effective (neo)adjuvant treatment
[12–14], that is why we incorporated a docetaxel containing
CT regimen in this trial. Third, preoperative treatment in-
creases the likelihood of tumour downsizing/downstaging
and to achieve tumour free resection margins [7, 16]. The
last consideration is that preoperative (chemo)radiotherapy
allows a more accurate definition of the radiation target
volume and margins, which may potentially limit toxicity in
patients receiving preoperative CRT.
Epirubicin containing CT regimens (epirubicin+cisplatin/
oxaliplatin+capecitabine; ECX/EOX) are widely used in the
preoperative setting, as recommended by European guide-
lines [9]. The choice to incorporate DOC as CT regimen
was based on several studies.
Naj Mohammad et al. investigated efficacy and safety of
triplet versus doublet CT in locally advanced or metastatic
oesophagogastric carcinoma. When subgroups were ex-
amined, especially triplet CT with taxane, cisplatin and
fluoropyrimidine revealed significant benefit [13]. Roth et
al. published in 2007 the results of a phase II trial among
121 patients. Patients were randomised between docetaxel
+cisplatin+5FU (DCF) and ECF. The regimen containing
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DCF seemed to be more effective than ECF. DCF had
shorter time-to-response, which may suggest that DCF is
more favourable as preoperative treatment compared to
ECF. However, DCF showed a trend towards increased
myelosuppression and infectious complications [12]. Van
Deenen et al. published in 2015 the results of a phase Ia/Ib
trial of DOC in patients with advanced cancer of the stom-
ach/GOJ. The data showed that the combination of intra-
venous docetaxel 50 mg/m2 and oxaliplatin 100 mg/m2 on
day 1 plus capecitabine 850 mg/m2 b.i.d. for 14 days in
3-week cycles were safe, tolerable and effective [15]. Toxic-
ities among 28 patients were frequent, as is often the case in
triple CT regimen, but remained non-severe and well man-
ageable in most patients. The most common grade ≥ 3 tox-
icities were leukocytopenia (15%) and neutropenia (24%).
Febrile neutropenia occurred in 12% of the patients, which
is less than the 29% reported for the combination of DCF,
reported by van Cutsem et al. [25].
Recently, the results of the FLOT4-AIO have been pre-
sented at the American Society of Clinical Oncology an-
nual meeting [14]. In this study, patients with resectable
gastric cancer or GOJ cancer, were randomised between
perioperative CT with ECF/ECX versus fluorouracil+leu-
covorin+oxaliplatin+docetaxel (FLOT). Perioperative CT
with ECF/ECX contained three pre- and postoperative cy-
cles and perioperative CT with FLOT contained four pre-
and postoperative cycles. Survival rates were significantly
improved in the FLOT arm. This study showed signifi-
cantly improved survival rates in the FLOT arm. Once the
key-publication is available, it is expected that European
guidelines will be updated. Various Dutch centres have
already implemented the FLOT-regimen as standard peri-
operative CT. The CT regimen used in the CRITCS-II
trial is a slight variation of FLOT, and the results of the
FLOT4-AIO study support the use of DOC as preopera-
tive CT in our study.
So far, this is the third randomised controlled trial in
which patients with upper GI cancer are treated with pre-
operative CRT. The CROSS study forms the basis for the
chosen CRT schedule [16]. One of the main concerns of
preoperative CRT is the potential increased risk for surgical
complications such as anastomotic leakage. The CROSS
study showed no difference in postoperative complication
rate between preoperative CRTand surgery alone [16]. Cur-
rently, the TOPGEAR study is recruiting patients. In this
study, patients with resectable gastric or GOJ cancer are 1:1
randomised to receive either preoperative CT or preopera-
tive CT followed by CRT, then followed by surgery and
postoperative CT [26]. Recently, the interim analysis of the
TOPGEAR trial has been published, which included a total
of 120 patients. It revealed no difference in surgical compli-
cations between both groups [27]. A retrospective analysis
from a prospectively maintained database from the MD An-
derson Cancer Center was published in 2017. This analysis
included a total of 346 patients with resectable gastric can-
cer, of whom 44% underwent preoperative CRT [28]. No
significant association between type of preoperative therapy
and the risk of anastomotic leakage was found.
Future perspectives
The aim of this study is to select the most promising pre-
operative treatment regimen among three experimental
arms in patients with resectable gastric adenocarcinoma.
This treatment regimen will subsequently be compared with
the current standard therapy in a phase III trial.
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